Amwell's DHA Sole-Source Win Marks a Strategic Inflection
The telehealth veteran edges closer to breakeven with a validated platform and a growing government franchise.
AMWL · Earnings Call · 2026-08-04
A Government Seal of Approval
The most significant news from Amwell's second-quarter 2026 report was the Defense Health Agency's (DHA) decision to award a sole-source contract directly to Amwell. As Chairman and CEO Ido Schoenberg stated, "The Defense Health Agency issued an intent to award notice for a sole-source contract directly with Amwell." This is a deliberate move to build the Military Health System's core platform around trusted partners. It provides long-term contract visibility (3-5 years) and reduces the dependency on middleware partners like Leidos, though they remain a collaborator.
This is not a simple renewal; it positions Amwell as one of five proprietary solution providers alongside Oracle Health, Philips, Solventum, and Henry Schein. The company expects a broader scope of services as it takes on additional responsibilities directly. This sole source designation is a powerful testament to the platform's value.
From Vendor to Infrastructure
Amwell has undergone a transformation from a telehealth vendor to an unified platform for AI-powered care. Subscription revenue now exceeds half of total revenue and grew sequentially this quarter. The platform model addresses payer pain points such as vendor fatigue and the desire for fewer, deeper partnerships. An independently funded study published in Nature Human Behaviour demonstrated that the SilverCloud behavioral health program more than doubled engagement, lowered rates of mental health disorders, and avoided an estimated $1.2 million in costs among 6,200 students over two years. This evidence is exactly what payers are seeking.
The Path to Breakeven
Financially, Amwell is closer than ever to its goal. Adjusted EBITDA loss narrowed to approximately $1 million in Q2, compared to a $4.7 million loss a year ago. As Schoenberg noted, "our adjusted EBITDA loss of approximately $1 million is the closest we have been to breakeven as a public company." The company raised its full-year adjusted EBITDA guidance to a loss of $9-7 million from $16-12 million, and reaffirmed its target of positive operating cash flow in Q4 2026.
Revenue declined 26.6% year-over-year to $52 million, but sequential subscription revenue increased 3.2%, signaling stabilization. The company ended the quarter with $196 million in cash and no debt. Total revenue has flattened around $55 million per quarter, a sharp recovery from the pandemic-era boom but a solid base for the upcoming growth.
The recent stock price action reflects the shifting sentiment: a 129% rally over the last 90 days. Yet the company still trades at just 0.4x price-to-revenue, reflecting skepticism that the market has not fully priced in the government opportunity.
What to Watch
The pipeline is the key variable. Management asserts that the government pipeline is a multiple of what it was a year ago, with potential to return to double-digit revenue growth in 2027. "We have the largest pipeline we have had in our history," said Schoenberg in a previous call, and the DHA win only accelerates that momentum. The renewal of the DHA contract and potential inclusion of behavioral health services are catalysts that could drive revenue growth in 2027.
Still, the company is intentionally divesting non-core assets to focus solely on the platform, which could create near-term revenue headwinds. The balance between focus and scale will be critical.
In summary, Amwell's transformation into a validated infrastructure for AI-powered care, combined with a landmark sole-source government contract and a path to cash-flow breakeven, marks a strategic inflection point. The next question is whether they can convert this into durable growth.
Amwell has completed its transformation. We have the platform, the proof, the partnerships, and the financial strength to lead as AI-powered care accelerates.